Receptor News and Research

RSS

Combination treatment extends lives of women with metastatic breast cancer

Changing the order in which two drugs are taken significantly extended the lives of women with metastatic breast cancer, a study has found.

8 Dec 2011

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced results from CLEOPATRA, the first randomized Phase III study of the investigational HER2-targeted medicine pertuzumab.

8 Dec 2011

Intensive maternal care during infancy promotes effect of NPY in brain

Neuropeptide Y (NPY) is the most abundant peptide hormone of the central nervous system. It is involved in various processes including stress management, the development of anxiety behaviour and body weight regulation. A collaborative research group including scientists from the Max Planck Institute for Medical Research in Heidelberg has demonstrated using mice that intensive maternal care during infancy promotes the effect of NPY in the brain.

8 Dec 2011

Majority of women do not receive guideline-recommended breast cancer adjuvant therapy

A first-of-its kind study led by Xiao-Cheng Wu, MD, MPH, Associate Professor of Public Health at LSU Health Sciences Center New Orleans, reports that a significant number of women are not receiving guideline-recommended treatment for breast cancer and what factors contribute.

7 Dec 2011

Scientists help uncover evolutionary history of TAS2R38 bitter taste receptor gene

Long the bane of picky eaters everywhere, broccoli's taste is not just a matter of having a cultured palate; some people can easily taste a bitter compound in the vegetable that others have difficulty detecting. Now a team of Penn researchers has helped uncover the evolutionary history of one of the genes responsible for this trait.

7 Dec 2011

INT-777 shows promise against metabolic syndrome

Heart disease is a major cause of death in industrialised countries, and is strongly associated with obesity and diabetes. Many scientists believe that what links these conditions is a chronic, low-grade inflammation.

7 Dec 2011

Study reveals previously unseen details of SBP8a anthrax bacteriophage

A new study has shown previously unseen details of an anthrax bacteriophage - a virus that infects anthrax bacteria - revealing for the first time how it infects its host, and providing an initial blueprint for how the phage might someday be modified into a tool for the detection and destruction of anthrax and other potential bioterror agents.

6 Dec 2011

Fruit fly and malaria mosquito sensors attuned to heat, chemical odors

Fruit flies and mosquitoes share similar sensory receptors that allow them to distinguish among thousands of sensory cues - particularly heat and chemical odors - as they search for food or try to avoid danger, researchers from Boston College and Brandeis University report in the current electronic edition of the journal Nature.

6 Dec 2011

EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it is presenting the comprehensive analysis of a recently completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia at the American College of Neuropsychopharmacology 50th Anniversary Annual Meeting.

5 Dec 2011

Targacept commences two clinical studies of TC-5619 for schizophrenia and ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of two clinical studies of TC-5619, a Phase 2b study evaluating the product candidate as a treatment for negative symptoms and cognitive dysfunction in schizophrenia and a Phase 2 study evaluating the product candidate in adults as a treatment for attention deficit/hyperactivity disorder (ADHD), inattentive-predominant.

5 Dec 2011

Study shows new biochemical disturbances in the brains of children with ADHD

A new study at örebro University in Sweden shows that children with ADHD have nearly 50 percent less of a protein that is important for attention and learning. The finding may mean that there are other biochemical disturbances in the brains of individuals with ADHD than was previously believed.

5 Dec 2011

Scientists discover new candidate gene for Dravet syndrome

Dravet syndrome is a severe genetic epilepsy that appears early in life. About 75 percent of cases can be attributed to mutations in the SCN1A gene encoding the sodium channel NaV1.1. The remaining patients with this syndrome are without a definitive molecular genetic diagnosis. Research presented today at the American Epilepsy Society's 65th Annual Meeting has found a non-SCN1A candidate gene and suggests that Dravet syndrome may be caused by any one of a number of yet unidentified genes.

5 Dec 2011

Researchers identify ADHD gene variants involved in glutamate signaling

Pediatric researchers analyzing genetic influences in attention-deficit/hyperactivity disorder (ADHD) have found alterations in specific genes involved in important brain signaling pathways. The study raises the possibility that drugs acting on those pathways might offer a new treatment option for patients with ADHD who have those gene variants—potentially, half a million U.S. children.

5 Dec 2011

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

HRF inhibitors may provide new therapeutic avenue for treatment of asthma and allergies

La Jolla Institute for Allergy & Immunology scientists have identified the histamine releasing factor (HRF) molecule as a promising target for developing new treatments for a number of allergic reactions including asthma.

3 Dec 2011

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

The American Society of Hematology (ASH) recognizes the following abstract presenters at the 53rd ASH annual meeting in San Diego, CA, with the highest scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow.

2 Dec 2011

Researchers identify cancer cell mitochondria as 'Achilles' heel' of tumor growth

Researchers at the Kimmel Cancer Center at Jefferson have identified cancer cell mitochondria as the unsuspecting powerhouse and "Achilles' heel" of tumor growth, opening up the door for new therapeutic targets in breast cancer and other tumor types.

2 Dec 2011

Idera receives FDA notification to proceed with IMO-3100 Phase 2 clinical trial for psoriasis

Idera Pharmaceuticals, Inc. today announced the receipt of verbal notification from the Food and Drug Administration that the company may proceed with a Phase 2 clinical trial of IMO-3100 in patients with psoriasis based on a trial protocol submitted by the company in October 2011.

2 Dec 2011

Researchers reveal ambivalent role of CXCL12/CXCR4 molecule in myocardial infarction

The chemokine CXCL12 acts as a chemical signal which mobilizes hematopoietic and other types of stem cells to leave the bone marrow and enter the circulation. Secretion of CXCL12 also guides these cells to sites at which the perfusion of tissue is sub-optimal due to localized obstruction of blood flow. These capabilities have made CXCL12 and its cognate receptor CXCR4 interesting candidates for therapies aimed at mitigating the effects of damage to the heart caused by myocardial infarction.

1 Dec 2011

arGEN-X closes EUR 27.5 million Series B fundraising round

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announced today the closing of a EUR 27.5 million (USD 37 million) Series B fundraising round, which was oversubscribed.

1 Dec 2011

Receptor News and Research

Combination treatment extends lives of women with metastatic breast cancer

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Intensive maternal care during infancy promotes effect of NPY in brain

Majority of women do not receive guideline-recommended breast cancer adjuvant therapy

Scientists help uncover evolutionary history of TAS2R38 bitter taste receptor gene

INT-777 shows promise against metabolic syndrome

Study reveals previously unseen details of SBP8a anthrax bacteriophage

Fruit fly and malaria mosquito sensors attuned to heat, chemical odors

EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

Targacept commences two clinical studies of TC-5619 for schizophrenia and ADHD

Study shows new biochemical disturbances in the brains of children with ADHD

Scientists discover new candidate gene for Dravet syndrome

Researchers identify ADHD gene variants involved in glutamate signaling

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

HRF inhibitors may provide new therapeutic avenue for treatment of asthma and allergies

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

Researchers identify cancer cell mitochondria as 'Achilles' heel' of tumor growth

Idera receives FDA notification to proceed with IMO-3100 Phase 2 clinical trial for psoriasis

Researchers reveal ambivalent role of CXCL12/CXCR4 molecule in myocardial infarction

arGEN-X closes EUR 27.5 million Series B fundraising round

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News